DESCRIPTIVE RESEARCH REPORTS

Thursday, April 4  ◆  11:45 am – 2:15 pm  ◆  Friday, April 5  ◆  10:45 am – 12:45 pm  ◆  Exhibit Hall B

Descriptive Research Reports describe new, improved or innovative roles or services in managed care pharmacy practice that are of such importance that they should be brought to the attention of other pharmacy professionals. The following posters were selected for presentation:

PRR-01: Comparison of Healthcare Resource Usage and Costs Before and After Initiating Treatment with Long-Acting Injectable Antipsychotics Among Medicaid Insured Schizophrenia Patients
Rimal Bera, MD, Clinical Professor, University of California Irvine, School of Medicine

PRR-02: Reducing Drug Diversion in North Carolina: Medicaid’s Lock-In Program
Janelle Sheen, PharmD, Manager, Clinical Services, Xerox State Healthcare, LLC

PRR-03: Period and Point Prevalence and Incidence Rate of New Use of Biologic Anti-Inflammatory Agents Among 2.6 Million Commercial Members Continuously Insured for 3 Years
Kevin Bowen, MD, MBA, Senior Health Outcomes Researcher, Prime Therapeutics LLC

PRR-04: Time to Discontinuation of Newly Initiated Biologic Therapy for Adult Crohn’s Disease (Infliximab Versus Adalimumab) and for Rheumatoid Arthritis (Infliximab Versus Adalimumab or Etanercept)
Kevin Bowen, MD, MBA, Senior Health Outcomes Researcher, Prime Therapeutics LLC

PRR-05: The 2012 U.S. Payor Landscape: Results from a Survey of Medical and Pharmacy Directors on Comparative Effectiveness Research
Richard Brook, MS, MBA, Vice President, JeSTARx Group

PRR-06: Economic Burden of Irritable Bowel Syndrome with Constipation: A Retrospective Analysis of All-Cause Healthcare Costs
Jessica Buono, MPH, Research Associate, Forest Research Institute, Inc.
PRR-07: Comparing Health Care Resource Utilization and Costs in Medicaid Beneficiaries with Schizophrenia and Schizoaffective Disorders Before and After Initiation of Clozapine Monotherapy
Dawn Velligan, PhD, Director, Division of Schizophrenia and Related Disorders, University of Texas Health Science Center
San Antonio, Psychiatry

PRR-08: Medical Costs Associated with Treatment Failure with Over-the-Counter or Prescription Constipation Treatments in Patients with IBS-C in a Medicaid Population
Robyn Carson, MPH, Associate Director, Health Economics and Outcomes Research, Forest Research Institute, Inc.

PRR-09: Impact of the Affordable Care Act (Health Care Reform) Provisions for Preventive Care Coverage on Pharmaceutical Costs and Utilization
Hing Chan, MS, MBA, Analytic Consultant, CVS Caremark

PRR-10: Outpatient Treatment and Clinical Characteristics of Patients with Aspergillosis in the United States
Paresh Chaudhari, PharmD, MPH, Senior Manager, Health Economics and Outcomes Research, Astellas Pharma US, Inc.

PRR-11: Evaluation of Increased Adherence and Cost Savings of an Employer Value Based Benefits Program Targeting Generic Antihyperlipidemic and Antidiabetic Medications
Bobby Clark, PhD, MHA, MS, MA, Director, Clinical Outcomes and Analytics, Walgreen Co.

PRR-12: Adherence to Antiretroviral Therapy in Managed Care Members in the United States: A Retrospective Claims Analysis
Catherine Cooke, PharmD, President, PosiHealth, Inc.

PRR-13: Cost Analysis of Certolizumab Pegol and Infliximab Therapy at 1 and 2 Years in Patients with Crohn's Disease
Fred Cox, PhD, Head, Health Economics and Outcomes Research, UCB Pharma

PRR-14: Units and Costs of Comparable Insulins Supplied to Patients: Is There a Difference by Manufacturer?
Elizabeth Eby, MPH, Research Scientist, Lilly USA, Inc.
PRR-15: Treatment Patterns and Healthcare Cost of Oncology Patients Treated with Bevacizumab in Hospital Outpatient and Office Settings
Nicole Engel-Nitz, PhD, Researcher, OptumInsight

PRR-16: Assessment of Prescription Utilization Patterns with the Shifts of Medicaid FFS to Managed Care in NY, KY, OH, and NJ
Angeli Garg, PharmD, MBA, Managed Markets Strategy and Analytics, IMS Health, Inc.

PRR-17: Association Between Adherence to Generic Statin Therapy and Outcomes: Total Cost of Care and Medical Events Over 2 Years
Patrick Gleason, PharmD, FCCP, BCPS, Director of Health Outcomes, Prime Therapeutics LLC

PRR-18: Lack of Overall Dose Escalation Between 2007 and 2012 with Etanercept (Enbrel) and Adalimumab (Humira)
Patrick Gleason, PharmD, FCCP, BCPS, Director of Clinical Outcomes, Prime Therapeutics LLC

PRR-19: Rheumatoid Arthritis Specialty Drug Utilizers Cost of Care Trends 2008 to 2010: An Integrated Medical and Pharmacy Claims Analysis
Patrick Gleason, PharmD, FCCP, BCPS, Director of Health Outcomes, Prime Therapeutics LLC

PRR-20: Immunosuppressant Waste Associated with 90 Day Supplies Compared to 30 Day Supplies of Calcineurin Inhibitors
Patrick Gleason, PharmD, FCCP, BCPS, Director of Health Outcomes, Prime Therapeutics LLC

PRR-21: Costs and Discontinuation Rates Among Protease Inhibitor Treated Hepatitis C Virus Patients In a Regional Health Plan
Boris Gorsh, PharmD, Manager, Clinical Programs, CDMI, LLC

PRR-22: Comparison of HealthCare Resource Utilization and Costs Between Patients who Received Trastuzumab in an Outpatient Hospital Versus Office Clinic Setting for the Treatment of Breast Cancer
Eduardo Santos, Senior Healthcare Economist, Genentech, A Member of the Roche Group
PRR-23: Using a Validated, Claims Data Based Algorithm to Evaluate the Effectiveness of Self-Injected Versus Infused Biologics for Rheumatoid Arthritis Claims Data
David Harrison, PhD, Health Economics Director, Amgen Inc.

PRR-24: Utilization of Infliximab in the Treatment of Inflammatory Bowel Disease in an Ambulatory Care Network in Northern California
Denis Ishisaka, PharmD, MS, FCSHP, Manager, Clinical Outcomes Research, Sutter Health

PRR-25: Measuring Brand Drug Coupon Availability and Relative Consumer Behavior Incentives by Drug Class and PBM Plan Design
Robert Jancaus, Advisor, CVS Caremark

PRR-26: Specialty Drugs are Forecasted to be 50% of All Drug Expenditures in 2018
Steven Johnson, PharmD, BCPS, Senior Director, Health Outcomes, Prime Therapeutics LLC

PRR-27: Evaluation of a Claims Based Algorithm to Determine the Effectiveness of Biologics for Rheumatoid Arthritis Using Commercial Claims Data
George Joseph, PhD, Health Economics Senior Manager, Amgen Inc.

PRR-28: Comparative Effectiveness of First-Line Subcutaneously Versus Intravenously Administered Biologics for Rheumatoid Arthritis Using a Validated, Claims Data Based Algorithm in a Large U.S. Commercial Health Plan
George Joseph, PhD, Health Economics Senior Manager, Amgen Inc.

PRR-29: Antiretroviral Persistence and Adherence and Total Healthcare Expenditures in Medicaid-Insured HIV Patients Initiating Current Guideline-Preferred Compared with Non-Preferred First-Line Antiretroviral Therapy
Timothy Juday, PhD, Director, U.S. Medical, Bristol-Myers Squibb

PRR-30: Health Care Expenditure Burden Among Elderly Patients with Cancer
Nasreen Khan, Senior Health Economist, Oxford Outcomes, an ICON plc company

PRR-31: Retrospective Evaluation of a Long-Acting Insulin Switch on Hemoglobin A1c: Glargine to Detemir (RELISH)
Kirstin Kim, PharmD, CDE, Ambulatory Care Pharmacist, Kaiser Permanente
Leanne Lai, PhD, Professor, Nova Southeastern University, College of Pharmacy

PRR-33: Utilization of Infliximab for the Treatment of Rheumatoid Arthritis in an Ambulatory Care Network in Northern California
Angela Leahy, PharmD, Clinical Outcomes Research Pharmacist, Sutter Health

PRR-34: Application of a Refill Reminder Program Aimed at Increasing Part D Plan Rating Medication Adherence Measures
Shelley Chun, PharmD, Director, Clinical Products and Analytics, MedImpact Healthcare Systems, Inc.

PRR-35: Evaluation of a Member-Directed Part D Medication Adherence Intervention
Bimal Patel, PharmD, Director, Health Outcomes Research, MedImpact Healthcare Systems, Inc.

PRR-36: Diminishing Rate of Return? Health Outcomes Associated with Initiation of Basal Insulin After 1, 2 or 3+ Oral Antidiabetic Drugs Among Managed Care Patients with Type 2 Diabetes
Philip Levin, MD, Endocrinologist, MODEL Clinical Research

PRR-37: Out-of-Pocket Costs and Prescription Reversals: The Case of Oral Linezolid
Anthony Louder, PhD, RPh, Research Scientist, Competitive Health Analytics, Inc.

Scott McClelland, PharmD, Director, Pharmacy Operations, Florida Blue

PRR-39: Healthcare Resource Utilization Following Initiation of a Triptan
Andrew Messali, PharmD, Intern, Allergan, Inc.

PRR-40: Trends in Utilization and Cost of Conventional and Biologic Therapies for Rheumatoid Arthritis
Lisa Mostovoy, PharmD, MBA, Clinical Manager, CVS Caremark

PRR-41: Existence and Impact of Geographic Access-Spillover on Drug Sales
Joseph Musumeci, Principal, SkyLaunch Advisors LLC
PRR-42: Treatment Patterns in Patients with HER2+ or ER/PR+ Metastatic Breast Cancer
Beth Nordstrom, PhD, Senior Research Scientist, United BioSource Corporation

PRR-43: Formulary Decision Makers’ Perceptions Regarding Value of Adherence Programs and Associated Outcomes Studies
Nathan White, CPC, Senior Director, Biotech and Specialty Services, Therigy

PRR-44: Economic Burden of Pain in a National Health Insurance Plan
Margaret Pasquale, PhD, Principal Researcher, Competitive Health Analytics, Inc.

PRR-45: Early Adherence with Disease Modifying Drugs Predicts Future Adherence in Patients with Multiple Sclerosis
Amy Phillips, PharmD, Associate Director, Health Outcomes and Market Access, EMD Serono, Inc.

PRR-46: Using Natural Language Processing to Identify Gout Flares and Evaluating Factors Associated with Refractory Chronic Gout Patients in a Managed Care Organization
Nazia Rashid, PharmD, MS, Research Scientist, Health Outcomes and Economics Researcher, Kaiser Permanente

PRR-47: Evaluation of Pharmacist Knowledge and Attitude Toward Pharmacogenomics
Renee Rayburg, RPh, Manager Clinical Pharmacy, OptumInsight

PRR-48: Impact of Refill and Save Program on Adherence to Desvenlafaxine and Healthcare Costs
Alesia Sadosky, PhD, MPH, MBA, Director, Pfizer Inc.

PRR-49: Final Results from the Multicenter COMPACT Study of Complications in Patients with Sickle Cell Disease and Utilization of Iron Chelation Therapy: A Retrospective Medical Records Review
Medha Sasane, BSPharmacy, PhD, Associate Director Outcomes Research, Novartis Pharmaceuticals Corporation

PRR-50: Impact of Offering Voluntary and Mandatory Mail Pricing Options at a Retail Pharmacy Network for a Large Trade Union Coalition
Aydin Sekili, MBA, Manager Analytic Consulting Services, CVS Caremark
PRR-51: Evaluation of Natalizumab (Tysabri) Utilization and Costs for Utilization Management Opportunities
Catherine Starner, PharmD, BCPS, Senior Health Outcomes Researcher, Prime Therapeutics LLC

PRR-52: Medicaid Pharmacy Benefit Carve-Ins and Their Impact on Generic Dispensing Rates and Program Costs
Corin Tablis, MBA, MPH, Senior Analytic Consultant, CVS Caremark

PRR-53: Prescription Savings Club Membership and Drug Utilization Behavior
Michael Taitel, PhD, Senior Director, Clinical Outcomes and Analytics, Walgreen Co.

PRR-54: Comparative Risks Associated with Off-Label Use of Individual Antipsychotic Drugs
Alexis Parente, PhD, Health Economics Outcomes Researcher, Inovalon Inc.

PRR-55: Use of Telaprevir Combination Treatment in Patients with Genotype 1 Chronic Hepatitis C Infection: Treatment Persistence and Early Virologic Response in a U.S. Community Setting
Montserrat Vera-Llonch, MD, MPH, Director, Health Value and Outcomes Research, Vertex Pharmaceuticals Incorporated

PRR-56: Contrasting Adherence Measurement Methods and Considerations for Case-Mix Adjustment Under Star Rating Program
Sharon Wang, PharmD, MS, Senior Health Outcomes Researcher, MedImpact Healthcare Systems, Inc.

PRR-57: Investigating the Association Between Copayment Status and Adherence for Statin Medications in a Veterans Administration Population
Rashid Kazerooni, PharmD, BCPS, Pharmacoeconomics Clinical Specialist, Veterans Affairs San Diego Healthcare System

PRR-58: Impact of Copayment Escalations on Simvastatin Users: Multi-Year Longitudinal Assessment in the MarketScan Commercial Database
Jonathan Watanabe, PharmD, PhD, Assistant Professor, Western University of Health Sciences, The College of Pharmacy

PRR-59: Disease-Modifying Therapy in Patients with Multiple Sclerosis: Treatment Patterns Over 2 Years
Jerrica Dodd, PharmD, MS, Medical and Outcomes Science Liaison, Neurology, Biogen Idec
PRR-60: Store and Prescription Characteristics Associated with Primary Medication Non-Adherence  
Donna West-Strum, RPh, PhD, Chair and Associate Professor, The University of Mississippi  

PRR-61: Health Care Costs Among Asthma Patients on Budesonide/Formoterol Combination (BFC) and Fluticasone/Salmeterol Combination (FSC)  
Setareh Williams, PhD, Director, Health Economics and Outcomes Research, AstraZeneca LP  

PRR-62: Retrospective Study of Persistence and Healthcare Charges Among Opioid-Dependent Patients Treated with Buprenorphine/Naloxone Film and Tablet Formulations Using a Privately Insured Retrospective Database  
Vladimir Zah, PhD, Health Economist, ZRx Outcomes Research Inc.  

PRR-63: Prescriber Interventions Targeting Gaps-in-Care for Persons with Diabetes Yield Measurable Medical Cost Savings  
Bill Zhang, PhD, Senior Manager, Clinical Outcomes and Pharmacoeconomics, Catamaran